Com de presse QMI SGM

SurgiMab > News & Events > News > SurgiMab and Quest Medical Imaging announce Collaboration Agreement for phase III Clinical Trial > Com de presse QMI SGM

19 September 2017 Administrateur SurgiMab0

Previous Post
SurgiMab and Quest Medical Imaging announce Collaboration Agreement for phase III Clinical Trial

Recent Posts

SurgiMab will sponsor the next edition of the International Symposium on Fluorescence Guided Surgery, 2-3 Nov 2023 in Amsterdam
SurgiMab will participate to the conference “Optics in the Life Sciences” during the Optica Biophotonics Congress in Vancouver April 23 – 27, 2023
SurgiMab co-sponsors the Molecular-Guided Surgery meeting that will take place during the SPIE Photonics West conference in San Francisco on Jan 22-23, 2022.
SurgiMab will attend the 7th Annual International Congress for Fluorescence-Guided Surgery – Coral Gables, FL, 15th and 16th feb. 2020.
SurgiMab sponsors the conference “Molecular-Guided Surgery” of the SPIE Photonics West meeting – San Francisco, 1st and 2nd feb. 2020.

Tumor detection Clinical development Company News & Events Contact

About SurgiMab

SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes.

Latest news

SurgiMab will sponsor the next edition of the International Symposium on Fluorescence Guided Surgery, 2-3 Nov 2023 in Amsterdam
SurgiMab will participate to the conference “Optics in the Life Sciences” during the Optica Biophotonics Congress in Vancouver April 23 – 27, 2023

Home . Legal & credits